Anti-CYP2D6 monoclonal antibody

Pre-made anti-CYP2D6 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to CYP2D6/CYP2D6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP0015-Ab-1/ GM-Tg-hg-IP0015-Ab-2Anti-Human CYP2D6 monoclonal antibodyHuman
GM-Tg-rg-IP0015-Ab-1/ GM-Tg-rg-IP0015-Ab-2Anti-Rat CYP2D6 monoclonal antibodyRat
GM-Tg-mg-IP0015-Ab-1/ GM-Tg-mg-IP0015-Ab-2Anti-Mouse CYP2D6 monoclonal antibodyMouse
GM-Tg-cynog-IP0015-Ab-1/ GM-Tg-cynog-IP0015-Ab-2Anti-Cynomolgus/ Rhesus macaque CYP2D6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP0015-Ab-1/ GM-Tg-felg-IP0015-Ab-2Anti-Feline CYP2D6 monoclonal antibodyFeline
GM-Tg-cang-IP0015-Ab-1/ GM-Tg-cang-IP0015-Ab-2Anti-Canine CYP2D6 monoclonal antibodyCanine
GM-Tg-bovg-IP0015-Ab-1/ GM-Tg-bovg-IP0015-Ab-2Anti-Bovine CYP2D6 monoclonal antibodyBovine
GM-Tg-equg-IP0015-Ab-1/ GM-Tg-equg-IP0015-Ab-2Anti-Equine CYP2D6 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP0015-Ab-1/ GM-Tg-hg-IP0015-Ab-2; GM-Tg-rg-IP0015-Ab-1/ GM-Tg-rg-IP0015-Ab-2;
GM-Tg-mg-IP0015-Ab-1/ GM-Tg-mg-IP0015-Ab-2; GM-Tg-cynog-IP0015-Ab-1/ GM-Tg-cynog-IP0015-Ab-2;
GM-Tg-felg-IP0015-Ab-1/ GM-Tg-felg-IP0015-Ab-2; GM-Tg-cang-IP0015-Ab-1/ GM-Tg-cang-IP0015-Ab-2;
GM-Tg-bovg-IP0015-Ab-1/ GM-Tg-bovg-IP0015-Ab-2; GM-Tg-equg-IP0015-Ab-1/ GM-Tg-equg-IP0015-Ab-2
Products NameAnti-CYP2D6 monoclonal antibody
Formatmab
Target NameCYP2D6
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-CYP2D6 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP0015-Ag-1Recombinant multi-species CP2D6/ CYP2D6/ CPD6 protein
    ORF Viral VectorvGMLP002840human CYP2D6 Lentivirus particle
    ORF Viral VectorpGMLP002840human CYP2D6 Lentivirus plasmid


    Target information

    Target IDGM-IP0015
    Target NameCYP2D6
    Gene ID1565,415120,100500743
    Gene Symbol and SynonymsCPD6,CYP2D,CYP2D15,CYP2D6,CYP2D7AP,CYP2D7BP,CYP2D7P2,CYP2D8P2,CYP2DL1,CYPIID15,CYPIID6,P450-DB1,P450C2D,P450DB1
    Uniprot AccessionP10635,Q29473
    Uniprot Entry NameCP2D6_HUMAN,CP2DF_CANLF
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target
    DiseaseCancer
    Gene EnsemblENSG00000100197
    Target ClassificationTumor-associated antigen (TAA)

    The target: CYP2D6, gene name: CYP2D6, also named as CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, P450-DB1, P450C2D, P450DB1. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize as many as 25% of commonly prescribed drugs. Its substrates include antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's substrates. Some individuals with the poor metabolizer phenotype have no functional protein since they carry 2 null alleles whereas in other individuals the gene is absent. This gene can vary in copy number and individuals with the ultrarapid metabolizer phenotype can have 3 or more active copies of the gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2014].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.